Pancreatic Stem/Progenitor Cells for the Treatment of Diabetes

Hirofumi Noguchi¹,²

¹ Regenerative Research Islet Transplant Program, Baylor Research Institute, 1400 8th Avenue, Fort Worth, TX 76104, USA. ² Institute of Biomedical Studies, Baylor University, Waco, TX 76798, USA. E-mail: hirofumi@baylorhealth.edu

Manuscript submitted June 23, 2010; resubmitted July 20, 2010; accepted July 22, 2010

Abstract

Patients with type 1 diabetes, and most patients with type 2 diabetes, have associated hyperglycemia due to the absence or reduction of insulin production by pancreatic β-cells. Surgical resection of the pancreas may also cause insulin-dependent diabetes depending on the size of the remaining pancreas. Insulin therapy has greatly improved the quality of life of diabetic patients, but this method is inaccurate and requires lifelong treatment that only mitigates the symptoms. The successes achieved over the last few decades by the transplantation of whole pancreas and isolated islets suggest that diabetes can be cured by the replenishment of deficient β-cells. These observations are proof-of-principle and have intensified interest in treating diabetes by cell transplantation, and by the use of stem cells. Pancreatic stem/progenitor cells could be one of the sources for the treatment of diabetes. Islet neogenesis, the budding of new islets from pancreatic stem/progenitor cells located in or near pancreatic ducts, has long been assumed to be an active process in the postnatal pancreas. Several in vitro studies have shown that insulin-producing cells can be generated from adult pancreatic ductal tissues. Acinar cells may also be a potential source for differentiation into insulin-producing cells. This review describes recent progress on pancreatic stem/progenitor cell research for the treatment of diabetes.

Keywords: diabetes · pancreatic stem/progenitor cells · duct · pancreatic endoderm · beta-cell · islet · acinar · islet transplantation

Introduction

Diabetes mellitus afflicts more than 200 million people worldwide. One of the primary effects is the reduction in β-cell mass. This is prevalent in all patients with type 1 diabetes, most patients with type 2 diabetes, and those with surgical diabetes (after pancreas resection). These metabolic disorders may result in the occurrence of severe systemic complications including diabetic neuropathy, nephropathy, retinopathy, heart diseases, and stroke during progression of the disease. The current therapy, using exogenous insulin supply, has greatly improved the quality of life for diabetic patients, especially type 1 diabetic patients. However, the method is inaccurate and does not completely control the minute-to-minute fluctuations in systemic blood glucose. As an alternative therapy, clinical studies have shown that pancreas, or islet, transplantation can support glucose homeostasis in type 1 diabetics, whose β-cells have been destroyed by an autoimmune reaction [1-6]. The advantages of islet transplantation, compared with traditional pancreas or pancreas-kidney transplantation, are the minimally invasive kind of intervention and fewer complications. However, limitations include the short supply of donor pancreata, the paucity of experienced islet isolation teams, side effects of immunosuppressants, and poor long-term results [6].
These limitations have led to a search for other sources of \( \beta \)-cells. Interest has gained in the differentiation of progenitor cells, and in the question whether they can be directed, or “programmed” efficiently. These programming efforts are based on present understanding of how \( \beta \)-cells are normally generated in the embryo, and how they arise during regeneration in adults, in response to tissue damage, and disease.

This article reviews recent progress in research on pancreatic stem/progenitor cells and their differentiation into insulin-producing cells. The in vivo stimulation of these pancreatic stem/progenitor cells, or transplantation of their ex vivo expanded differentiated progenies, could represent potential strategies for diabetes treatment.

**Pancreas development and key transcription factors**

The vertebrate pancreas has its embryological origin in two endodermal buds that develop on the dorsal and ventral side of the duodenum [7-9]. The dorsal bud grows just below the notochord, while the ventral bud develops adjacent to the hepatic diverticulum [10]. These two pancreatic buds grow, branch, and fuse, to form the definitive pancreas composed of exocrine and endocrine cells (Figure 1). During development, cells in the pancreatic anlage migrate from the ducts, while differentiating into insulin-producing cells. The endocrine cells or islets of Langerhans, composed of \( \alpha \), \( \beta \), \( \delta \), \( \varepsilon \), and PP, respectively secreting glucagon, insulin, somatostatin, ghrelin, and pancreatic polypeptide hormones into the bloodstream.

Several classes of transcription factors are involved in the specification and differentiation of both endocrine and exocrine lineages. The newly specified pancreatic endoderm is initially marked by the expression of the pancreatic and duodenal homeobox gene 1 (Pdx1; also known as Ipf1), and by the pancreas-specific transcription factor 1a (Ptf1a) [12, 13]. Both transcription factors are critical for pancreatic development. Pdx1 is expressed at the earliest stages in the dorsal and ventral pancreatic buds, as well as in the duodenum [14]. At later stages, it is highly expressed in \( \beta \)-cells, with lower levels also found in acinar cells and all rostral duodenal cells [15]. Pdx1 levels help to control the balance between endocrine and exocrine (acinar and duct) progenitors which differentiate within the pancreas [16]. Mice lacking Pdx1 do not develop a pancreas [17, 18], and mutations in the human homologue are associated with pancreatic agenesis [19]. Ptf1a is a basic helix-loop-helix (bHLH) gene that is expressed in early pancreatic progenitors (dorsal and ventral buds) [20]. In adults, it is only expressed in acinar cells [21]. Loss-of-function studies in mice have demonstrated that Ptf1a is essential for acinar cell development, and plays an important role in endocrine cell development as well [20, 22]. In humans, PTF1A gene mutations are associated with pancreatic and cerebellar agenesis [23].

**Abbreviations:**
- bHLH - basic helix-loop-helix
- CA 19-9 - carbohydrate antigen 19-9 (glycoprotein)
- CA II - carbonic anhydrase II
- CD34 - cluster of differentiation 34 (surface glycoprotein, cell-cell adhesion factor, mediates attachment of stem cells to bone marrow)
- CD45 - cluster of differentiation 45 (surface glycoprotein, cell-cell adhesion factor, mediates attachment of stem cells to bone marrow)
- CD45 - cluster of differentiation 45 (signaling molecule, known as protein tyrosine phosphatase receptor type C)
- CD133 - cluster of differentiation 133 (surface glycoprotein, also known as Prominin 1 (PRO1M), expressed by different stem and progenitor cells)
- CK-19 - cytokeratin 19 (expressed in epithelial cells of pancreatic ducts)
- Cre recombinase - type I topoisomerase (catalyzes site-specific recombinase of DNA between loxP sites)
- CreER - inducible Cre recombinase (fusion protein to induce recombinase activity)
- CreloxP - recombination system to delete DNA sequences in living organisms
- GFP - green fluorescent protein
- GLP-1 - glucagon-like peptide 1
- Ipf1 - insulin promoter factor 1 (also known as Pdx1)
- LacZ - structural gene of lac-operon (codes for the enzyme \( \beta \)-galactosidase, splits lactose into galactose und glucose)
- LoxP - locus of crossover in P1 (can be catalyzed by Cre)
- MafA - v-maf musculoaponeurotic fibrosarcoma oncogene homolog A
- mTert - mouse telomerase reverse transcriptase
- NeuroD - neurogenic differentiation (also known as BET2; bHLH transcription factor expressed in pancreatic cells)
- Ngn3 - neurogenin 3 (member of the bHLH family of transcription factors expressed in the nervous system)
- Pdx1 - pancreatic and duodenal homebox 1 (transcription factor necessary for pancreas development)
- Ptf1a - pancreas-specific transcription factor 1a
- ROSA26 - gene locus in mice (commonly used to knock-in cDNA constructs for ubiquitous or conditional gene expression in transgenic mice)
- Ter199 - \( \gamma \)-glutamyl-(S)-(benzyl)cysteiny1-(R)-(−)-phenylglycine diethyl ester (inhibitor of glutathione S-transferases)
Notch signaling also helps to regulate the balance of exocrine and endocrine cells, probably by allowing the expansion of an undifferentiated pancreatic progenitor population [24-26]. Loss of Notch signaling allows the endocrine lineage to develop, which requires, and is marked by, the bHLH transcription factor, neurogenin 3 (Ngn3) [12, 24, 27]. Mice lacking Ngn3 do not develop endocrine cells, and exhibit disordered acinar polarity. Ngn3 directly influences the expression of another islet-specific bHLH gene, neurogenic differentiation (NeuroD; also known as BETA2) [28]. A loss of NeuroD/BETA2 function implicates a phenotype similar to Ngn3, but with less severity. This phenotype leads to a diminished number of all endocrine cell types [29], and definitive β-cells are generated under the influence of the v-mafmusculoaponeuroticfibrosarcoma oncogene homolog A (MafA) transcription factor [30, 31].

Tissue-specific stem/progenitor cells in the pancreas

The existence of true pancreatic “stem” cells is still controversial. At present, common wisdom considers that the bulk of normal islet renewal and pancreas regeneration following damage (such as 90% pancreatectomy and partial duct ligation), is achieved by β-cell replication [32] and/or differentiation of pancreatic (NGN-3-expressing) progenitor cells located near or within ducts [33]. In fact, putative pancreatic stem cells have been isolated from adult rodent pancreas. In addition to others, we have shown that isolated mouse pancreatic stem cells are capable of self-renew and multipotency [34, 35]. These cells were isolated from a duct-rich population, and expressed PDX1 transcription factor and cytokeratin (CK)-19. The cells differentiated into insulin-, glucagon-, and somatostatin-producing cells [34, 35]. These two studies demonstrated the possibility of multipotent stem cells located within or near adult pancreatic ducts. On the other hand, human cells from the duct-rich population were unable to divide after 30 days, even under several culture conditions. However, they were able to differentiate into insulin-producing cells [36]. There are some differences in the methodologies used in the two studies, e.g. culture conditions, isolation stress, and differences in the species.

In our study, human pancreatic stem cells were unable to maintain an undifferentiated state under any of the selected culture conditions. Given that the culture conditions for embryonic stem cells are different between human and mouse, we consider that further evaluation of other culture conditions needs to be carried out. It is possible that pancreas preservation and/or isolation stress affect the survival of human pancreatic stem cells, because human islet isolation is more stressful for cells than mouse islet isolation. Another possibility is that the mouse pancreas contains stem cells, whereas the human pancreas does not. Although many researchers have shown that there are pancreatic “progenitor” cells in the human pancreas which have multipotent capacity to differentiate into insulin-, glu-

Figure 1. Schematic representation of pancreas development. The embryonic pancreas in vertebrates forms from a dorsal and ventral protrusion of the primitive gut epithelium. These two pancreatic buds grow, branch, and fuse to form the definitive pancreas.
cagon- and somatostatin-producing cells, no one has shown so far whether there are human pancreatic “stem” cells with multipotent and self-renew capacity. The identification and study of tissue stem/progenitor cells has been facilitated by the generation of transgenic mouse models such as the mouse telomerase reverse transcriptase (mTert)-driven green fluorescent protein (GFP) mouse [37]. GFP-positive cells were found in the non-islet pancreatic tissue after treatment for 3 days with exendin-4, the analog of glucagon-like peptide 1 (GLP-1) [38]. This finding suggests the presence of activated stem cells in the mouse pancreas.

The advantage of tissue-specific stem/progenitor cells is their attribution to a specific differentiation pathway, which may require less in vitro manipulation to obtain fully functional β-cells than the use of less committed pluripotent stem cells. β-cells have a limited ability to expand, especially in the adult mouse and human, such that their restricted growth ability does not permit recovery from cell loss in type 1 diabetes [39]. Therefore, it is important to identify pancreatic stem/progenitor cells, especially “stem” cells which have self-renew capacity to yield a sufficient number of β-cells for the treatment of diabetes.

**Pancreatic duct cells**

During embryonic development, pancreatic cells migrate from the ducts, differentiate to form clusters, and finally become islets [11]. Therefore, the postnatal pancreatic duct may be the main source of progenitors for pancreatic growth and regeneration. Several in vitro studies have shown that insulin-producing cells can be generated from adult pancreatic ductal tissues [40-46]. Human adult ductal tissues cultured with matrigel formed islet-like buds, and differentiated into endocrine cells [41, 42]. Moreover, ductal cells purified from dispersed islet-depleted human pancreatic tissue using CA19-9 antibody differentiated into insulin-producing cells [46]. Other groups showed the isolation of multipotent pancreatic progenitors from both neonatal and adult pancreata using fluorescent activated cell sorting [44, 45]. The cells purified with CD133 (+), CD34 (-), CD45 (-), Ter199 (-) expressed the duct marker, CK-19 and could differentiate into pancreatic endocrine and acinar cells. It was also shown that GFP-negative pancreatic tissue from transgenic mice expresses GFP under the control of the mouse insulin promoter. When this tissue was cultured for 1 week, 1-3% of the cells expressed GFP [47].

Inada et al. generated transgenic mice expressing human carbonic anhydrase II (CAII) promoter-Cre recombinase, or the inducible form CreER, to cross with ROSA26 loxP-Stop-loxP LacZ reporter mice [48]. These genetic lineage-tracing experiments showed that within the pancreas, CA-II-expressing cells act as progenitors giving rise to new islets and acini, which emerge normally after birth and after injury (ductal ligation). Another study showed activation of NGN-3-expressing cells located near or within ducts. These cells contributed to new β-cell formation after partial duct ligation in adult mice [33]. Hence, there are clear indications that duct cells can act as pancreatic progenitors in adult rodents.

The Edmonton group attempted to define a correlation between graft cellular composition and long-term transplant success, using eighty-three...
transplanted human islet grafts [49, 50]. A significant positive correlation was observed between the number of ductal-epithelial cells transplanted, and long-term metabolic success, as assessed by an intravenous glucose tolerance test at approximately two years post-transplantation. Whereas, no significant correlation was observed between the total islet equivalents and long-term metabolic success. This data showed that the presence of ductal cells in clinical islet transplantation may improve the long-term metabolic outcome.

Pancreatic acinar cells

The transdifferentiation of acinar cells into islets has also been proposed [51-53]. Initial studies showed that acinar cells from human pancreas were able to transdifferentiate into pancreatic duct cells expressing CK-19 [54]. Baeyens et al. showed that manipulations of cell culture conditions have yielded functional β-cells from rat exocrine cells with a combination of EGF and leukemia inhibitory factor [52]. Minami et al. showed that pancreatic acinar cells could transdifferentiate into insulin-secreting cells with secretory properties similar to those of native pancreatic β-cells [53]. The frequency of insulin-positive cells was only 0.01% in the initial preparation and increased to approximately 5% under culture conditions. Analysis by the Cre/loxP-based direct cell lineage-tracing system indicates that these new cells originate from amylase/elastase-expressing pancreatic acinar cells.

Melton’s group showed in vivo reprogramming of adult pancreatic exocrine cells to yield β-cells [55]. Using a strategy of re-expressing key developmental regulators in vivo through adeno viral delivery, they identified a specific combination of three transcription factors (Pdx1, Ngn3, and MafA) that reprogrammed the differentiated pancreatic exocrine cells in adult mice into cells that closely resemble β-cells. The induced β-cells were able to ameliorate hyperglycemia by remodeling local vasculature and secreting insulin. Interestingly, the direct shift from acinar to β-cells did not involve activation of the cell cycle or dedifferentiation. For this reason, the forced reprogramming of exocrine cells cannot be regarded as evidence for the potential of progenitor cells under unmanipulated conditions. This approach might have lower risk of tumor formation than one that involves a self-renewable, pluripotent cell type. However, the use of virus vectors is a disadvantage of this study.

Other stem cells and future prospects

The generation of β-cells may be accomplished through the differentiation of stem/progenitor cells derived from endoderm in other organs such as liver and gastrointestinal tract [56-66], embryonic stem (ES) cells [67, 68], and induced pluripotent stem (iPS) cells [69] (Figure 2). Recent progress in the search for new sources of β-cells has opened up several possibilities for the development of new treatments for diabetes. The issue of how stem/progenitor cells could be induced to yield fully functional islets is unresolved so far. We need further investigations to establish cell-based therapies for the potential treatment and cure of diabetes.

Acknowledgements: The author wishes to thank Dr. Steven Phillips for editing the manuscript.

Disclosures (conflict of interests statement): The author reports no conflict of interests.

References

10. Slack JM. Developmental biology of the pan-
creaD development 1995. 121:1569-1580.


42. Pancreatic Stem/Progenitor Cells


